Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic

Our plain-English summary of Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic, by L. Käsmann, J. Taugner, A. Nieto, et al (Journal of Clinical Medicine, 2022).

The study

• Authors: L. Käsmann, J. Taugner, A. Nieto, C. Belka, C. Eze, F. Manapov
• Journal: Journal of Clinical Medicine
• Published: 2022;11(19)
• Type of article: Editorial
• Cited by: 4 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Thoracic radiotherapy (TRT) plays an integral role in the multimodal treatment of lung cancer, breast cancer, esophageal cancer, thymoma and mesothelioma, having been used as either a definitive, neoadjuvant or adjuvant treatment or for palliative intention to achieve symptom control [...].

In plain English

This article was an editorial, not an original study, by authors from the Department of Radiation Oncology at University Hospital, LMU Munich, Germany. It reported no new patient data and did not discuss asbestos. Mesothelioma appeared only in a list of cancers, alongside lung, breast and esophageal cancer and thymoma, that are treated with radiotherapy to the chest. The editorial described radiation-induced lung injury, which can appear as radiation pneumonitis (lung inflammation) or lung fibrosis (scarring), as a severe complication of this treatment. Drawing on published work, the authors wrote that symptomatic radiation pneumonitis is treated with corticosteroids, and that none of the agents investigated could be recommended to prevent radiation pneumonitis or lung fibrosis. They noted that COVID-19 pneumonia and radiation pneumonitis share similar symptoms, although radiation pneumonitis is usually on one side and its scan changes match the radiation treatment fields. They stated that the two conditions occurring together had not been described in the literature. The authors concluded that any patient suspected of having radiation pneumonitis should be tested for SARS-CoV-2 infection, to tell the two apart and guide treatment.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: editorial (no original data)
• Who was studied: No study population. The editorial discusses patients receiving thoracic radiotherapy for lung cancer, breast cancer, esophageal cancer, thymoma and mesothelioma.
• Exposure: Thoracic radiotherapy, and SARS-CoV-2 infection in the COVID-19 pandemic. No asbestos exposure is discussed.
• Main results:
  • The authors described radiation-induced lung injury (radiation pneumonitis or lung fibrosis) as a severe, dose-limiting complication of thoracic radiotherapy (a statement supported by cited literature, not new data).
  • Citing guidelines, the authors wrote that corticosteroids are the recommended treatment for symptomatic radiation pneumonitis.
  • The authors wrote that no successful treatment for lung fibrosis has been established.
  • The authors wrote that none of the agents investigated could be recommended to prevent radiation pneumonitis or lung fibrosis.
  • The authors wrote that the clinical symptoms of SARS-CoV-2 interstitial pneumonia and radiation pneumonitis are quite similar.
  • The authors wrote that radiation pneumonitis is usually one-sided, with imaging abnormalities that correspond to the radiation treatment fields.
  • The authors stated that combined radiation pneumonitis and SARS-CoV-2 interstitial pneumonia had not been described in the literature.
• The authors' conclusion: The authors concluded that any patient suspected of having radiation pneumonitis should be tested for SARS-CoV-2 infection, to tell the two conditions apart and guide treatment without delay.

Topics

Medical terms in this study, explained in our Lexicon: Lung Cancer, Esophageal Cancer, Mesothelioma, Palliative Care.

Related studies

• Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups — O. Glehen, V. Kepenekian, et al. (2020)
• Short-Term Outcomes of COVID-19 Pandemic on Non-Small Cell Lung Cancer Screening and Management — F. Orelaru, M. Edwards, et al. (2023)
• Pleural mesothelioma incidence and use of systemic treatment decreased during the COVID-19 pandemic in The Netherlands — I. Smesseim, L.H. Douma, et al. (2025)
• [Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups] — O. Glehen, V. Kepenekian, et al. (2020)
• Mortality rates from asbestos-related diseases in Italy during the first year of the COVID-19 pandemic — L. Fazzo, E. Grande, et al. (2023)
• Different imaging methods in the assessment of radiation-induced lung injury following hemithorax irradiation for pleural mesothelioma — P. Maasilta, L. Kivisaari, et al. (1990)

Browse more research in Journal of Clinical Medicine, or return to medical research.